Seattle-based biotech company Proniras raised $4.65 million in a recent Series B funding round to support its tezampanel, an opiate withdrawal therapy and Proniras’ leading program.
Proniras, which is now in the clinical stages, will use the funding to support tezampanel’s Phase I clinical study. The treatment operates by regulating brain activation in areas that affect mental illness, addiction and withdrawal. If successful, tezampanel could improve current treatments available for opioid overdose, withdrawal and remission.
The funding brings Proniras a step closer to its Series B goal of $9 million, which it says will support research and development efforts.